Clinical Trials Browser

Phase 2 × INDUSTRY × encorafenib × Clear all

NCT05217446 2026-03-18

SEAMARK

Phase 2 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05926960 2026-03-09

PORTSIDE

Phase 2 Terminated

Melanoma, Skin Neoplasms

NCT05195632 2026-01-07

OCEANII

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03915951 2025-11-17

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Phase 2 Completed

98 enrolled 18 charts 1 FDA

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT05004350 2025-04-15

NAUTICALCRC

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT02159066 2024-03-05

LOGIC-2

Phase 2 Completed

158 enrolled 40 charts

Melanoma

NCT03693170 2024-02-02

ANCHOR-CRC

Phase 2 Completed

95 enrolled 30 charts

Gastrointestinal

Colorectal Neoplasms

NCT03911869 2023-05-31

POLARIS

Phase 2 Terminated

13 enrolled 55 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT01981187 2021-03-26

SIGNATURE

Phase 2 Terminated

12 enrolled 13 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT02109653 2020-11-13

Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT01820364 2017-01-09

LOGIC

Phase 2 Terminated

15 enrolled 13 charts

Melanoma